Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Systematic Review Article

萘醌类维生素K治疗癌症的疗效:系统综述和荟萃分析

卷 21, 期 6, 2021

发表于: 20 January, 2021

页: [495 - 513] 页: 19

弟呕挨: 10.2174/1568009621999210120182834

价格: $65

摘要

背景：癌细胞代谢改变的氧化还原失调促进了癌细胞的增殖、侵袭和抵抗治疗。相反，这些特征代表了恶性细胞的特定脆弱性，可以选择性地靶向氧化还原化疗。其中，维生素K (VitK)具有对抗癌症干细胞的潜力，以及其他肿瘤块。 目的：通过系统综述和混合方法的meta分析，评估维生素K治疗癌症的可能益处和安全性。 方法：在几个电子数据库中进行了系统的搜索，以比较维生素K治疗与对照组结合和不结合的研究。对于定量研究，评估了全部或部分报告的临床结果，如复发率、生存率、总体反应和不良反应。对于定性研究，完成了综述。 结果：分析结果显示，与安慰剂组相比，维生素K治疗组的临床疗效、无进展生存的合并风险比、总生存的合并相对风险和总缓解显著升高(p<0.05)。我们没有观察到两组不良事件发生的任何显著差异。在定性研究中，针对骨髓增生异常综合征和晚期实体瘤的维生素K治疗分别导致了24.1%和10%的临床反应。 结论：维生素K不仅对多种肿瘤类型具有抗肿瘤作用，而且与其他治疗药物具有良好的协同作用。

关键词: 维生素K，系统综述，萘醌类，抗肿瘤作用，安全性，协同作用，化疗，多效作用

« Previous Next »
图形摘要

[1]
Aromataris, E.; Pearson, A. The systematic review: an overview. Am. J. Nurs., 2014, 114(3), 53-58.
[http://dx.doi.org/10.1097/01.NAJ.0000444496.24228.2c] [PMID: 24572533]
[2]
Munn, Z.; Stern, C.; Aromataris, E.; Lockwood, C.; Jordan, Z. What Kind of systematic review should i conduct? A proposed typology and guidance for systematic reviewers in the medical and health sciences. BMC Med. Res. Method., 2018, 18(1), 1-9.
[3]
Egger, M.; Schneider, M.; Davey Smith, G. Spurious precision? Meta-analysis of observational studies. BMJ, 1998, 316(7125), 140-144.
[http://dx.doi.org/10.1136/bmj.316.7125.140] [PMID: 9462324]
[4]
Pearson, A.; White, H.; Bath-Hextall, F.; Salmond, S.; Apostolo, J.; Kirkpatrick, P. A mixed-methods approach to systematic reviews. Int. J. Evid.-Based Healthc., 2015, 13(3), 121-131.
[http://dx.doi.org/10.1097/XEB.0000000000000052] [PMID: 26196082]
[5]
Pazdernik, T.L.; Kerecsen, L. Chemotherapeutic Drugs, 3rd ed.; Rapid Review series; Elsevier Health Sciences, 2010.
[http://dx.doi.org/10.1016/B978-0-323-06812-3.00029-8]
[6]
Wondrak, G.T. Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid. Redox Signal., 2009, 11(12), 3013-3069.
[http://dx.doi.org/10.1089/ars.2009.2541] [PMID: 19496700]
[7]
Ivanova, D.; Zhelev, Z.; Getsov, P.; Nikolova, B.; Aoki, I.; Higashi, T.; Bakalova, R.; Vitamin, K. Vitamin K: Redox-modulation, prevention of mitochondrial dysfunction and anticancer effect. Redox Biol., 2018, 16, 352-358.
[http://dx.doi.org/10.1016/j.redox.2018.03.013] [PMID: 29597144]
[8]
Fisher, G.R.; Gutierrez, P.L. Free radical formation and DNA strand breakage during metabolism of diaziquone by NAD(P)H quinone-acceptor oxidoreductase (DT-diaphorase) and NADPH cytochrome c reductase. Free Radic. Biol. Med., 1991, 11(6), 597-607.
[http://dx.doi.org/10.1016/0891-5849(91)90141-O] [PMID: 1663902]
[9]
Saify, Z.S.; Mushtaq, N.; Noor, F.; Takween, S.; Arif, M. Role of quinone moiety as antitumour agents: A review. Pak. J. Pharm. Sci., 1999, 12(2), 21-31.
[PMID: 16414830]
[10]
Nicotera, P.; Hinds, T.R.; Nelson, S.D.; Vincenzi, F.F. Differential effects of arylating and oxidizing analogs of N-acetyl-p-benzoquinoneimine on red blood cell membrane proteins. Arch. Biochem. Biophys., 1990, 283(1), 200-205.
[http://dx.doi.org/10.1016/0003-9861(90)90631-8] [PMID: 2146923]
[11]
Sreelatha, T.; Kandhasamy, S.; Dinesh, R.; Shruthy, S.; Shweta, S.; Mukesh, D.; Karunagaran, D.; Balaji, R.; Mathivanan, N.; Perumal, P.T. Synthesis and SAR study of novel anticancer and antimicrobial naphthoquinone amide derivatives. Bioorg. Med. Chem. Lett., 2014, 24(15), 3647-3651.
[http://dx.doi.org/10.1016/j.bmcl.2014.04.080] [PMID: 24913712]
[12]
Liew, S.K.; Malagobadan, S.; Arshad, N.M.; Nagoor, N.H. A review of the structure-activity relationship of natural and synthetic antimetastatic compounds. Biomolecules, 2020, 10(1), 138.
[http://dx.doi.org/10.3390/biom10010138] [PMID: 31947704]
[13]
Lu, J-J.; Bao, J-L.; Wu, G-S.; Xu, W-S.; Huang, M-Q.; Chen, X-P.; Wang, Y-T. Quinones derived from plant secondary metabolites as anti-cancer agents. Anticancer. Agents Med. Chem., 2013, 13(3), 456-463.
[http://dx.doi.org/10.2174/1871520611313030008] [PMID: 22931417]
[14]
von Ardenne, M.; Reitnauer, P.G. Selektive in-vivo-thermosensibilisierung und therapie des ehrlich-mäsue-ascites-karzinoms durch vitamin-K3-natrium-bisulfit. Dtsch. Gesundheitsw., 1967, 22(40), 1879-1885.
[PMID: 5600833]
[15]
Nagourney, R.; Weisenthal, L.; Dill, P.; Just, R.; Fass, L.; Baker, J. Menadiol in combination with cytotoxic chemotherapies; the feasibility for resistance modification in human cancers: A pilot study. Proc. Am. Soc. Clin. Oncol., 1987, 6, 35.
[16]
Hong, Q.N.; Fàbregues, S.; Bartlett, G.; Boardman, F.; Cargo, M.; Dagenais, P.; Gagnon, M.P.; Griffiths, F.; Nicolau, B.; O’Cathain, A.; Rousseau, M.C.; Vedel, I.; Pluye, P. The mixed methods appraisal tool (MMAT) version 2018 for information professionals and Res. Educ. Inf., 2018, 34(4), 285-291.
[http://dx.doi.org/10.3233/EFI-180221]
[17]
Jung, D-H.; Hwang, S.; Song, G-W.; Ryoo, B-Y.; Kim, N.; Tak, E.; Hong, H-N. An interim safety analysis of hepatocellular carcinoma patients administrating oral vitamin K with or without sorafenib. Korean J. Hepatobiliary Pancreat. Surg., 2015, 19(1), 1-5.
[http://dx.doi.org/10.14701/kjhbps.2015.19.1.1] [PMID: 26155269]
[18]
Hosho, K.; Okano, J.I.; Koda, M.; Murawaki, Y. Vitamin K2 Has No Preventive Effect on Recurrence of Hepatocellular Carcinoma after Effective Treatment. Yonago Acta Med., 2008, 51(4), 95-99.
[19]
Haruna, Y.; Inoue, A.; Kawamoto, S. Efficacy and safety of vitamin K with sorafenib combination treatment against hepatocellular carcinoma: Open-label, randomized phase II study. J. Clin. Oncol., 2017, 35(15), 15665-15665.
[20]
Haruna, Y.; Hasegawa, N.; Imanaka, K.; Kawamoto, S.; Inoue, A. Clinical impact of vitamin K dosing on sorafenib treatment for hepatocellular carcinoma. J. Cancer, 2017, 8(11), 1988-1994.
[http://dx.doi.org/10.7150/jca.18900] [PMID: 28819398]
[21]
Sarin, S.K.; Kumar, M.; Garg, S.; Hissar, S.; Pandey, C.; Sharma, B.C. High dose vitamin K3 infusion in advanced hepatocellular carcinoma. J. Gastroenterol. Hepatol., 2006, 21(9), 1478-1482.
[http://dx.doi.org/10.1111/j.1440-1746.2006.04383.x] [PMID: 16911696]
[22]
Akiyama, N.; Miyazawa, K.; Kanda, Y.; Tohyama, K.; Omine, M.; Mitani, K.; Ohyashiki, K. Multicenter phase II trial of vitamin K(2) monotherapy and vitamin K(2) plus 1α-hydroxyvitamin D(3) combination therapy for low-risk myelodysplastic syndromes. Leuk. Res., 2010, 34(9), 1151-1157.
[http://dx.doi.org/10.1016/j.leukres.2010.04.006] [PMID: 20569983]
[23]
Abe, Y.; Muta, K.; Hirase, N.; Choi, I.; Matsushima, T.; Hara, K.; Taguchi, F.; Suematsu, E.; Shibata, K.; Uike, N.; Nishimura, J.; Nawata, H. Vitamin K2 therapy for myelodysplastic syndrome. Japanese J. Clin. Hematol; , 2002, 43, pp. 117-121.
[24]
Miyazawa, K.; Nishimaki, J.; Ohyashiki, K.; Enomoto, S.; Kuriya, S.; Fukuda, R.; Hotta, T.; Teramura, M.; Mizoguchi, H.; Uchiyama, T.; Omine, M. Vitamin K2 therapy for myelodysplastic syndromes (MDS) and post-MDS acute myeloid leukemia: information through a questionnaire survey of multi-center pilot studies in Japan. Leukemia, 2000, 14(6), 1156-1157.
[http://dx.doi.org/10.1038/sj.leu.2401790] [PMID: 10865985]
[25]
Yoshinaga, K.; Teramura, M.; Hida, M.; Masuda, M.; Motoji, T. Vitamin K Therapy for Myelodysplastic Syndrome, Experience in TWMU. The 65th annual meeting of the Japanese Society of Hematology, 2003, 878(378)
[26]
Takami, A.; Asakura, H.; Nakao, S. Menatetrenone, a vitamin K2 analog, ameliorates cytopenia in patients with refractory anemia of myelodysplastic syndrome. Ann. Hematol., 2002, 81(1), 16-19.
[http://dx.doi.org/10.1007/s00277-001-0391-x] [PMID: 11807630]
[27]
Lim, D.; Morgan, R.J., Jr; Akman, S.; Margolin, K.; Carr, B.I.; Leong, L.; Odujinrin, O.; Doroshow, J.H.; Phase, I. Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy. Invest. New Drugs, 2005, 23(3), 235-239.
[http://dx.doi.org/10.1007/s10637-005-6731-2] [PMID: 15868379]
[28]
Tareen, B.; Summers, J.L.; Jamison, J.M.; Neal, D.R.; McGuire, K.; Gerson, L.; Diokno, A. A 12 week, open label, phase I/IIa study using apatone for the treatment of prostate cancer patients who have failed standard therapy. Int. J. Med. Sci., 2008, 5(2), 62-67.
[http://dx.doi.org/10.7150/ijms.5.62] [PMID: 18392145]
[29]
Hotta, N.; Ayada, M.; Sato, K.; Ishikawa, T.; Okumura, A.; Matsumoto, E.; Ohashi, T.; Kakumu, S. Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma. Hepatogastroenterology, 2007, 54(79), 2073-2077.
[PMID: 18251162]
[30]
Tetef, M.; Margolin, K.; Ahn, C.; Akman, S.; Chow, W.; Coluzzi, P.; Leong, L.; Morgan, R.J., Jr; Raschko, J.; Shibata, S.; Somlo, G.; Doroshow, J.H. Mitomycin C and menadione for the treatment of advanced gastrointestinal cancers: a phase II trial. J. Cancer Res. Clin. Oncol., 1995, 121(2), 103-106.
[http://dx.doi.org/10.1007/BF01202221] [PMID: 7883772]
[31]
Tetef, M.; Margolin, K.; Ahn, C.; Akman, S.; Chow, W.; Leong, L.; Morgan, R.J., Jr; Raschko, J.; Somlo, G.; Doroshow, J.H. Mitomycin C and menadione for the treatment of lung cancer: a phase II trial. Invest. New Drugs, 1995, 13(2), 157-162.
[http://dx.doi.org/10.1007/BF00872865] [PMID: 8617579]
[32]
Margolin, K.A.; Akman, S.A.; Leong, L.A.; Morgan, R.J.; Somlo, G.; Raschko, J.W.; Ahn, C.; Doroshow, J.H.; Phase, I. Phase I study of mitomycin C and menadione in advanced solid tumors. Cancer Chemother. Pharmacol., 1995, 36(4), 293-298.
[http://dx.doi.org/10.1007/BF00689046] [PMID: 7628048]
[33]
Habu, D.; Shiomi, S.; Tamori, A.; Takeda, T.; Tanaka, T.; Kubo, S.; Nishiguchi, S. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA, 2004, 292(3), 358-361.
[http://dx.doi.org/10.1001/jama.292.3.358] [PMID: 15265851]
[34]
Lasalvia-Prisco, E.; Cucchi, S.; Vázquez, J.; Lasalvia-Galante, E.; Golomar, W.; Gordon, W. Serum markers variation consistent with autoschizis induced by ascorbic acid-menadione in patients with prostate cancer. Med. Oncol., 2003, 20(1), 45-52.
[http://dx.doi.org/10.1385/MO:20:1:45] [PMID: 12665684]
[35]
Abe, Y.; Muta, K.; Hirase, N.; Choi, I.; Matsushima, T.; Hara, K.; Taguchi, F.; Suematsu, E.; Shibata, K.; Uike, N.; Nishimura, J.; Nawata, H. Vitamin K2 therapy for myelodysplastic syndrome. Rinsho Ketsueki, 2002, 43(2), 117-121.
[http://dx.doi.org/10.11406/rinketsu.43.117] [PMID: 11925874]
[36]
Ishizuka, M.; Kubota, K.; Shimoda, M.; Kita, J.; Kato, M.; Park, K.H.; Shiraki, T. Effect of menatetrenone, a vitamin k2 analog, on recurrence of hepatocellular carcinoma after surgical resection: a prospective randomized controlled trial. Anticancer Res., 2012, 32(12), 5415-5420.
[PMID: 23225445]
[37]
Kakizaki, S.; Sohara, N.; Sato, K.; Suzuki, H.; Yanagisawa, M.; Nakajima, H.; Takagi, H.; Naganuma, A.; Otsuka, T.; Takahashi, H.; Hamada, T.; Mori, M. Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J. Gastroenterol. Hepatol., 2007, 22(4), 518-522.
[http://dx.doi.org/10.1111/j.1440-1746.2007.04844.x] [PMID: 17376044]
[38]
Kubota, K.; Sawada, T.; Kita, J.; Shimoda, M.; Kato, M. 6594 POSTER effect of menatetrenone, a vitamin K2 analog, on recurrence of hepatocellular carcinoma after surgical resection – final results of randomized controlled study. Eur. J. Cancer, 2011, 47, S470.
[http://dx.doi.org/10.1016/S0959-8049(11)71905-0]
[39]
Mizuta, T.; Ozaki, I.; Eguchi, Y.; Yasutake, T.; Kawazoe, S.; Fujimoto, K.; Yamamoto, K. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer, 2006, 106(4), 867-872.
[http://dx.doi.org/10.1002/cncr.21667] [PMID: 16400650]
[40]
Yoshida, H.; Shiratori, Y.; Kudo, M.; Shiina, S.; Mizuta, T.; Kojiro, M.; Yamamoto, K.; Koike, Y.; Saito, K.; Koyanagi, N.; Kawabe, T.; Kawazoe, S.; Kobashi, H.; Kasugai, H.; Osaki, Y.; Araki, Y.; Izumi, N.; Oka, H.; Tsuji, K.; Toyota, J.; Seki, T.; Osawa, T.; Masaki, N.; Ichinose, M.; Seike, M.; Ishikawa, A.; Ueno, Y.; Tagawa, K.; Kuromatsu, R.; Sakisaka, S.; Ikeda, H.; Kuroda, H.; Kokuryu, H.; Yamashita, T.; Sakaida, I.; Katamoto, T.; Kikuchi, K.; Nomoto, M.; Omata, M. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology, 2011, 54(2), 532-540.
[http://dx.doi.org/10.1002/hep.24430] [PMID: 21574174]
[41]
Yoshiji, H.; Noguchi, R.; Toyohara, M.; Ikenaka, Y.; Kitade, M.; Kaji, K.; Yamazaki, M.; Yamao, J.; Mitoro, A.; Sawai, M.; Yoshida, M.; Fujimoto, M.; Tsujimoto, T.; Kawaratani, H.; Uemura, M.; Fukui, H. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J. Hepatol., 2009, 51(2), 315-321.
[http://dx.doi.org/10.1016/j.jhep.2009.04.011] [PMID: 19501932]
[42]
Carr, B.I.; Wang, Z.; Wang, M.; Wei, G. Differential effects of vitamin K1 on AFP and DCP levels in patients with unresectable HCC and in HCC cell lines. Dig. Dis. Sci., 2011, 56(6), 1876-1883.
[http://dx.doi.org/10.1007/s10620-010-1521-x] [PMID: 21188521]
[43]
Ryan, R. How to GRADE the quality of the evidence. Cochrane Consumers and Communication Group. Version 1.0, 2016.http://cccrg.cochrane.org/author-resourceshttps://www.scirp.org/(S(vtj3fa45qm1ean45vvffcz55))/reference/ReferencesPapers.aspx?ReferenceID=2553049
[44]
Page, M.J.; Moher, D. Evaluations of the uptake and impact of the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and extensions: a scoping review. Syst. Rev., 2017, 6(1), 263.
[http://dx.doi.org/10.1186/s13643-017-0663-8] [PMID: 29258593]
[45]
Tierney, J.F.; Stewart, L.A.; Ghersi, D.; Burdett, S.; Sydes, M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 2007, 8, 16.
[http://dx.doi.org/10.1186/1745-6215-8-16] [PMID: 17555582]
[46]
Parmar, M.K.B.; Torri, V.; Stewart, L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat. Med., 1998, 17(24), 2815-2834.
[http://dx.doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8] [PMID: 9921604]
[47]
Chatellier, G.; Zapletal, E.; Lemaitre, D.; Menard, J.; Degoulet, P. The number needed to treat: a clinically useful nomogram in its proper context. BMJ, 1996, 312(7028), 426-429.
[http://dx.doi.org/10.1136/bmj.312.7028.426] [PMID: 8601116]
[48]
WHO. Cancer. https://www.who.int/health-topics/cancer
[49]
Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin., 2015, 65(2), 87-108.
[http://dx.doi.org/10.3322/caac.21262] [PMID: 25651787]
[50]
Verrax, J.; Taper, H.; Buc Calderon, P. Targeting cancer cells by an oxidant-based therapy. Curr. Mol. Pharmacol., 2008, 1(1), 80-92.
[http://dx.doi.org/10.2174/1874467210801010080] [PMID: 20021426]
[51]
Jamison, J.M.; Gilloteaux, J.; Taper, H.S.; Calderon, P.B.; Summers, J.L. Autoschizis: a novel cell death. Biochem. Pharmacol., 2002, 63(10), 1773-1783.
[http://dx.doi.org/10.1016/S0006-2952(02)00904-8] [PMID: 12034362]
[52]
Calderon, P.B.; Cadrobbi, J.; Marques, C.; Hong-Ngoc, N.; Jamison, J.M.; Gilloteaux, J.; Summers, J.L.; Taper, H.S. Potential therapeutic application of the association of vitamins C and K3 in cancer treatment. Curr. Med. Chem., 2002, 9(24), 2271-2285.
[http://dx.doi.org/10.2174/0929867023368674] [PMID: 12470246]
[53]
Verrax, J.; Cadrobbi, J.; Delvaux, M.; Jamison, J.M.; Gilloteaux, J.; Summers, J.L.; Taper, H.S.; Buc Calderon, P. The association of vitamins C and K3 kills cancer cells mainly by autoschizis, a novel form of cell death. Basis for their potential use as coadjuvants in anticancer therapy. Eur. J. Med. Chem., 2003, 38(5), 451-457.
[http://dx.doi.org/10.1016/S0223-5234(03)00082-5] [PMID: 12767595]
[54]
Sata, N.; Klonowski-Stumpe, H.; Han, B.; Häussinger, D.; Niederau, C. Menadione induces both necrosis and apoptosis in rat pancreatic acinar AR4-2J cells. Free Radic. Biol. Med., 1997, 23(6), 844-850.
[http://dx.doi.org/10.1016/S0891-5849(97)00064-6] [PMID: 9378363]
[55]
O’Brien, P.J. Molecular mechanisms of quinone cytotoxicity. Chem. Biol. Interact., 1991, 80(1), 1-41.
[http://dx.doi.org/10.1016/0009-2797(91)90029-7] [PMID: 1913977]
[56]
Lamson, D.W.; Plaza, S.M. The anticancer effects of vitamin K. Altern. Med. Rev., 2003, 8(3), 303-318.
[PMID: 12946240]
[57]
Tabrizian, P.; Jibara, G.; Shrager, B.; Schwartz, M.; Roayaie, S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann. Surg., 2015, 261(5), 947-955.
[http://dx.doi.org/10.1097/SLA.0000000000000710] [PMID: 25010665]
[58]
Neuzil, J.; Stantic, M.; Zobalova, R.; Chladova, J.; Wang, X.; Prochazka, L.; Dong, L.; Andera, L.; Ralph, S.J. Tumour-initiating cells vs. cancer ‘stem’ cells and CD133: what’s in the name? Biochem. Biophys. Res. Commun., 2007, 355(4), 855-859.
[http://dx.doi.org/10.1016/j.bbrc.2007.01.159] [PMID: 17307142]
[59]
Zhou, B.B.S.; Zhang, H.; Damelin, M.; Geles, K.G.; Grindley, J.C.; Dirks, P.B. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov., 2009, 8(10), 806-823.
[http://dx.doi.org/10.1038/nrd2137] [PMID: 19794444]
[60]
Wicha, M.S.; Liu, S.; Dontu, G. Cancer stem cells: an old idea--a paradigm shift. Cancer Res., 2006, 66(4), 1883-1890.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-3153] [PMID: 16488983]
[61]
Bansal, N.; Banerjee, D. Tumor initiating cells. Curr. Pharm. Biotechnol., 2009, 10(2), 192-196.
[http://dx.doi.org/10.2174/138920109787315015] [PMID: 19199951]
[62]
Yan, B.; Dong, L.; Neuzil, J. Mitochondria: An intriguing target for killing tumour-initiating cells. Mitochondrion, 2016, 26, 86-93.
[http://dx.doi.org/10.1016/j.mito.2015.12.007] [PMID: 26702582]
[63]
Parker, G.C.; Acsadi, G.; Brenner, C.A. Mitochondria: Determinants of Stem Cell Fate?; Stem Cells and Development: United States, 2009, pp. 803-806.
[64]
Nesti, C.; Pasquali, L.; Vaglini, F.; Siciliano, G.; Murri, L. The role of mitochondria in stem cell biology. Biosci. Rep., 2007, 27(1-3), 165-171.
[http://dx.doi.org/10.1007/s10540-007-9044-1] [PMID: 17484045]
[65]
Neuzil, J.; Dong, L.F.; Rohlena, J.; Truksa, J.; Ralph, S.J. Classification of mitocans, anti-cancer drugs acting on mitochondria. Mitochondrion, 2013, 13(3), 199-208.
[http://dx.doi.org/10.1016/j.mito.2012.07.112] [PMID: 22846431]
[66]
Sasaki, R.; Suzuki, Y.; Yonezawa, Y.; Ota, Y.; Okamoto, Y.; Demizu, Y.; Huang, P.; Yoshida, H.; Sugimura, K.; Mizushina, Y. DNA polymerase γ inhibition by vitamin K3 induces mitochondria-mediated cytotoxicity in human cancer cells. Cancer Sci., 2008, 99(5), 1040-1048.
[http://dx.doi.org/10.1111/j.1349-7006.2008.00771.x] [PMID: 18312466]
[67]
Tanaka, T.; Taniguchi, T.; Sannomiya, K.; Takenaka, H.; Tomonari, T.; Okamoto, K.; Kitamura, S.; Okahisa, T.; Tamaki, K.; Mikasa, H.; Suzuki, S.; Takayama, T. Novel des-γ-carboxy prothrombin in serum for the diagnosis of hepatocellular carcinoma. J. Gastroenterol. Hepatol., 2013, 28(8), 1348-1355.
[http://dx.doi.org/10.1111/jgh.12166] [PMID: 23432345]
[68]
Bertino, G.; Ardiri, A.M.; Boemi, P.M.; Ierna, D.; Interlandi, D.; Caruso, L.; Minona, E.; Trovato, M.A.; Vicari, S.; Li Destri, G.; Puleo, S. A study about mechanisms of des-gamma-carboxy prothrombin’s production in hepatocellular carcinoma. Panminerva Med., 2008, 50(3), 221-226.
[PMID: 18927526]
[69]
Zhang, Y.S.; Chu, J.H.; Cui, S.X.; Song, Z.Y.; Qu, X.J. Des-γ-carboxy prothrombin (DCP) as a potential autologous growth factor for the development of hepatocellular carcinoma. Cell. Physiol. Biochem., 2014, 34(3), 903-915.
[http://dx.doi.org/10.1159/000366308] [PMID: 25200250]
[70]
Ertle, J.M.; Heider, D.; Wichert, M.; Keller, B.; Kueper, R.; Hilgard, P.; Gerken, G.; Schlaak, J.F. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma. Digestion, 2013, 87(2), 121-131.
[http://dx.doi.org/10.1159/000346080] [PMID: 23406785]
[71]
Yamamoto, K.; Imamura, H.; Matsuyama, Y.; Hasegawa, K.; Beck, Y.; Sugawara, Y.; Makuuchi, M.; Kokudo, N. Significance of alpha-fetoprotein and des-γ-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann. Surg. Oncol., 2009, 16(10), 2795-2804.
[http://dx.doi.org/10.1245/s10434-009-0618-y] [PMID: 19669841]
[72]
Zakhary, N.I.; Khodeer, S.M.; Shafik, H.E.; Abdel Malak, C.A. Impact of PIVKA-II in diagnosis of hepatocellular carcinoma. J. Adv. Res., 2013, 4(6), 539-546.
[http://dx.doi.org/10.1016/j.jare.2012.10.004] [PMID: 25685463]
[73]
Gentile, I.; Buonomo, A.R.; Scotto, R.; Zappulo, E.; Carriero, C.; Piccirillo, M.; Izzo, F.; Rizzo, M.; Cerasuolo, D.; Borgia, G.; Cavalcanti, E. Diagnostic Accuracy of PIVKA-II, Alpha-Fetoprotein and a Combination of Both in Diagnosis of Hepatocellular Carcinoma in Patients Affected by Chronic HCV Infection.In Vivo (Brooklyn); , 2017, 31, pp. (4)695-700.
[74]
Kim, H.S.; Park, J.W.; Jang, J.S.; Kim, H.J.; Shin, W.G.; Kim, K.H.; Lee, J.H.; Kim, H.Y.; Jang, M.K. Prognostic values of α-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study. J. Clin. Gastroenterol., 2009, 43(5), 482-488.
[http://dx.doi.org/10.1097/MCG.0b013e318182015a] [PMID: 19197197]
[75]
Marrero, J.A.; Feng, Z.; Wang, Y.; Nguyen, M.H.; Befeler, A.S.; Roberts, L.R.; Reddy, K.R.; Harnois, D.; Llovet, J.M.; Normolle, D.; Dalhgren, J.; Chia, D.; Lok, A.S.; Wagner, P.D.; Srivastava, S.; Schwartz, M. α-fetoprotein, des-γ carboxyprothrombin, and lectin-bound α-fetoprotein in early hepatocellular carcinoma. Gastroenterology, 2009, 137(1), 110-118.
[http://dx.doi.org/10.1053/j.gastro.2009.04.005] [PMID: 19362088]
[76]
Baek, Y.H.; Lee, J.H.; Jang, J.S.; Lee, S.W.; Han, J.Y.; Jeong, J.S.; Choi, J.C.; Kim, H.Y.; Han, S.Y. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP. Hepatogastroenterology, 2009, 56(91-92), 763-767.
[PMID: 19621698]
[77]
Carr, B.I.; Kanke, F.; Wise, M.; Satomura, S. Clinical evaluation of lens culinaris agglutinin-reactive α-fetoprotein and des-γ-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig. Dis. Sci., 2007, 52(3), 776-782.
[http://dx.doi.org/10.1007/s10620-006-9541-2] [PMID: 17253135]
[78]
Hitomi, M.; Yokoyama, F.; Kita, Y.; Nonomura, T.; Masaki, T.; Yoshiji, H.; Inoue, H.; Kinekawa, F.; Kurokohchi, K.; Uchida, N.; Watanabe, S.; Kuriyama, S. Antitumor effects of vitamins K1, K2 and K3 on hepatocellular carcinoma in vitro and in vivo. Int. J. Oncol., 2005, 26(3), 713-720.
[http://dx.doi.org/10.3892/ijo.26.3.713] [PMID: 15703828]
[79]
Hitomi, M.; Nonomura, T.; Yokoyama, F.; Yoshiji, H.; Ogawa, M.; Nakai, S.; Deguchi, A.; Masaki, T.; Inoue, H.; Kimura, Y.; Kurokohchi, K.; Uchida, N.; Kuriyama, S. In vitro and in vivo antitumor effects of vitamin K5 on hepatocellular carcinoma. Int. J. Oncol., 2005, 26(5), 1337-1344.
[http://dx.doi.org/10.3892/ijo.26.5.1337] [PMID: 15809726]
[80]
Kuriyama, S.; Hitomi, M.; Yoshiji, H.; Nonomura, T.; Tsujimoto, T.; Mitoro, A.; Akahane, T.; Ogawa, M.; Nakai, S.; Deguchi, A.; Masaki, T.; Uchida, N. Vitamins K2, K3 and K5 exert in vivo antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules. Int. J. Oncol., 2005, 27(2), 505-511.
[http://dx.doi.org/10.3892/ijo.27.2.505] [PMID: 16010434]
[81]
Matsumoto, K.; Okano, J.; Nagahara, T.; Murawaki, Y. Apoptosis of liver cancer cells by vitamin K2 and enhancement by MEK inhibition. Int. J. Oncol., 2006, 29(6), 1501-1508.
[http://dx.doi.org/10.3892/ijo.29.6.1501] [PMID: 17088989]
[82]
Xia, J.; Ozaki, I.; Matsuhashi, S.; Kuwashiro, T.; Takahashi, H.; Anzai, K.; Mizuta, T. Mechanisms of PKC-mediated enhancement of HIF-1α activity and its inhibition by vitamin K2 in hepatocellular carcinoma cells. Int. J. Mol. Sci., 2019, 20(5)E1022
[http://dx.doi.org/10.3390/ijms20051022] [PMID: 30813635]
[83]
Takami, A.; Nakao, S.; Ontachi, Y.; Yamauchi, H.; Matsuda, T. Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog. Int. J. Hematol., 1999, 69(1), 24-26.
[PMID: 10641439]
[84]
Sada, E.; Abe, Y.; Ohba, R.; Tachikawa, Y.; Nagasawa, E.; Shiratsuchi, M.; Takayanagi, R. Vitamin K2 modulates differentiation and apoptosis of both myeloid and erythroid lineages. Eur. J. Haematol., 2010, 85(6), 538-548.
[http://dx.doi.org/10.1111/j.1600-0609.2010.01530.x] [PMID: 20887388]
[85]
Yaguchi, M.; Miyazawa, K.; Otawa, M.; Katagiri, T.; Nishimaki, J.; Uchida, Y.; Iwase, O.; Gotoh, A.; Kawanishi, Y.; Toyama, K. Vitamin K2 selectively induces apoptosis of blastic cells in myelodysplastic syndrome: flow cytometric detection of apoptotic cells using APO2.7 monoclonal antibody. Leukemia, 1998, 12(9), 1392-1397.
[http://dx.doi.org/10.1038/sj.leu.2401143] [PMID: 9737687]
[86]
Djuric, Z.; Corbett, T.H.; Valeriote, F.A.; Heilbrun, L.K.; Baker, L.H. Detoxification ability and toxicity of quinones in mouse and human tumor cell lines used for anticancer drug screening. Cancer Chemother. Pharmacol., 1995, 36(1), 20-26.
[http://dx.doi.org/10.1007/BF00685727] [PMID: 7720171]
[87]
Shi, J.; Zhou, S.; Kang, L.; Ling, H.; Chen, J.; Duan, L.; Song, Y.; Deng, Y. Evaluation of the antitumor effects of vitamin K2 (menaquinone-7) nanoemulsions modified with sialic acid-cholesterol conjugate. Drug Deliv. Transl. Res., 2018, 8(1), 1-11.
[http://dx.doi.org/10.1007/s13346-017-0424-1] [PMID: 28849577]
[88]
Li, S.; Zhang, T.; Xu, W.; Ding, J.; Yin, F.; Xu, J.; Sun, W.; Wang, H.; Sun, M.; Cai, Z.; Hua, Y. Sarcoma-targeting peptide-decorated polypeptide nanogel intracellularly delivers shikonin for upregulated osteosarcoma necroptosis and diminished pulmonary metastasis. Theranostics, 2018, 8(5), 1361-1375.
[http://dx.doi.org/10.7150/thno.18299] [PMID: 29507626]
[89]
Su, Y.; Huang, N.; Chen, D.; Zhang, L.; Dong, X.; Sun, Y.; Zhu, X.; Zhang, F.; Gao, J.; Wang, Y.; Fan, K.; Lo, P.; Li, W.; Ling, C. Successful in vivo hyperthermal therapy toward breast cancer by Chinese medicine shikonin-loaded thermosensitive micelle. Int. J. Nanomedicine, 2017, 12, 4019-4035.
[http://dx.doi.org/10.2147/IJN.S132639] [PMID: 28603416]
[90]
Winter, G.E.; Radic, B.; Mayor-Ruiz, C.; Blomen, V.A.; Trefzer, C.; Kandasamy, R.K.; Huber, K.V.M.; Gridling, M.; Chen, D.; Klampfl, T.; Kralovics, R.; Kubicek, S.; Fernandez-Capetillo, O.; Brummelkamp, T.R.; Superti-Furga, G. The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. Nat. Chem. Biol., 2014, 10(9), 768-773.
[http://dx.doi.org/10.1038/nchembio.1590] [PMID: 25064833]
[91]
Blanco, E.; Bey, E.A.; Khemtong, C.; Yang, S.G.; Setti-Guthi, J.; Chen, H.; Kessinger, C.W.; Carnevale, K.A.; Bornmann, W.G.; Boothman, D.A.; Gao, J. Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Res., 2010, 70(10), 3896-3904.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-3995] [PMID: 20460521]
[92]
Chrastina, A.; Baron, V.T.; Abedinpour, P.; Rondeau, G.; Welsh, J.; Borgström, P. Plumbagin-loaded nanoemulsion drug delivery formulation and evaluation of antiproliferative effect on prostate cancer cells. BioMed Res. Int., 2018, 2018, 9035452.
[http://dx.doi.org/10.1155/2018/9035452] [PMID: 30534567]
[93]
Sakpakdeejaroen, I.; Somani, S.; Laskar, P.; Irving, C.; Mullin, M.; Dufès, C. Anti-tumor activity of intravenously administered plumbagin entrapped in targeted nanoparticles. J. Biomed. Nanotechnol., 2020, 16(1), 85-100.
[http://dx.doi.org/10.1166/jbn.2020.2874] [PMID: 31996288]
[94]
Kaneki, M.; Hosoi, T.; Ouchi, Y.; Orimo, H. Pleiotropic actions of vitamin K: protector of bone health and beyond? Nutrition, 2006, 22(7-8), 845-852.
[http://dx.doi.org/10.1016/j.nut.2006.05.003] [PMID: 16815498]
[95]
Shukla, S.; Srivastava, R.S.; Shrivastava, S.K.; Sodhi, A.; Kumar, P. Synthesis, characterization and antiproliferative activity of 1,2-naphthoquinone and its derivatives. Appl. Biochem. Biotechnol., 2012, 167(5), 1430-1445.
[http://dx.doi.org/10.1007/s12010-012-9551-9] [PMID: 22258648]
[96]
Fazeli, M.R.; Amin, G.; Attari, M.M.A.; Ashtiani, H.; Jamalifar, H.; Samadi, N. Antimicrobial activities of iranian sumac and avishan-e shirazi (Zataria Multiflora) against some food-borne bacteria. Food Control, 2007, 18(6), 646-649.
[http://dx.doi.org/10.1016/j.foodcont.2006.03.002]
[97]
Mojaddar Langroodi, A.; Tajik, H.; Mehdizadeh, T. Antibacterial and antioxidant characteristics of Zataria Multiflora boiss essential oil and hydroalcoholic extract of fhus coriaria L. J. Food Qual. Hazards Control, 2019, 6(1), 16-24.
[http://dx.doi.org/10.18502/jfqhc.6.1.454]
[98]
Evenepoel, P.; Claes, K.; Meijers, B.; Laurent, M.; Bammens, B.; Naesens, M.; Sprangers, B.; Pottel, H.; Cavalier, E.; Kuypers, D. Poor vitamin K status is associated with low bone mineral density and increased fracture risk in end-stage renal disease. J. Bone Miner. Res., 2019, 34(2), 262-269.
[http://dx.doi.org/10.1002/jbmr.3608] [PMID: 30427544]
[99]
Pazyar, N.; Houshmand, G.; Yaghoobi, R.; Hemmati, A.A.; Zeineli, Z.; Ghorbanzadeh, B. Wound healing effects of topical Vitamin K: A randomized controlled trial. Indian J. Pharmacol., 2019, 51(2), 88-92.
[http://dx.doi.org/10.4103/ijp.IJP_183_18] [PMID: 31142943]
[100]
Oikonomaki, T.; Papasotiriou, M.; Ntrinias, T.; Kalogeropoulou, C.; Zabakis, P.; Kalavrizioti, D.; Papadakis, I.; Goumenos, D.S.; Papachristou, E. The effect of vitamin K2 supplementation on vascular calcification in haemodialysis patients: a 1-year follow-up randomized trial. Int. Urol. Nephrol., 2019, 51(11), 2037-2044.
[http://dx.doi.org/10.1007/s11255-019-02275-2] [PMID: 31529295]
[101]
Witham, M.D.; Price, R.J.G.; Band, M.M.; Hannah, M.S.; Fulton, R.L.; Clarke, C.L.; Donnan, P.T.; McNamee, P.; Cvoro, V.; Soiza, R.L. Effect of vitamin K2 on postural sway in older people who fall: A randomized controlled trial. J. Am. Geriatr. Soc., 2019, 67(10), 2102-2107.
[http://dx.doi.org/10.1111/jgs.16024] [PMID: 31211416]
[102]
Zwakenberg, S.R.; de Jong, P.A.; Bartstra, J.W.; van Asperen, R.; Westerink, J.; de Valk, H.; Slart, R.H.J.A.; Luurtsema, G.; Wolterink, J.M.; de Borst, G.J.; van Herwaarden, J.A.; van de Ree, M.A.; Schurgers, L.J.; van der Schouw, Y.T.; Beulens, J.W.J. The effect of menaquinone-7 supplementation on vascular calcification in patients with diabetes: a randomized, double-blind, placebo-controlled trial. Am. J. Clin. Nutr., 2019, 110(4), 883-890.
[http://dx.doi.org/10.1093/ajcn/nqz147] [PMID: 31387121]
[103]
Ntaios, G.; Pearce, L.A.; Meseguer, E.; Endres, M.; Amarenco, P.; Ozturk, S.; Lang, W.; Bornstein, N.M.; Molina, C.A.; Pagola, J.; Mundl, H.; Berkowitz, S.D.; Liu, Y.Y.; Sen, S.; Connolly, S.J.; Hart, R.G. Aortic arch atherosclerosis in patients with embolic stroke of undetermined source: An exploratory analysis of the navigate esus trial. Stroke, 2019, 50(11), 3184-3190.
[http://dx.doi.org/10.1161/STROKEAHA.119.025813] [PMID: 31526123]
[104]
Torbergsen, A.C.; Watne, L.O.; Frihagen, F.; Wyller, T.B.; Mowè, M. Effects of nutritional intervention upon bone turnover in elderly hip fracture patients. Randomized controlled trial. Clin. Nutr. ESPEN, 2019, 29, 52-58.
[http://dx.doi.org/10.1016/j.clnesp.2017.11.012] [PMID: 30661701]
[105]
Coppens, M.; Weitz, J.I.; Eikelboom, J.W.A. Synergy of dual pathway inhibition in chronic cardiovascular disease. Circ. Res., 2019, 124(3), 416-425.
[http://dx.doi.org/10.1161/CIRCRESAHA.118.313141] [PMID: 30702997]
[106]
Hashimoto, H.; Iwasa, S.; Yanai-Takahashi, T.; Honma, Y.; Kato, K.; Hamaguchi, T.; Yamada, Y.; Shimada, Y.; Yamazaki, N.; Kato, Y. Randomized, double-blind, placebo-controlled phase Ⅱ study on the efficacy and safety of vitamin K1 ointment for cetuximab or panitumumab-induced acneiform eruptions-VIKTORIA study. Gan To Kagaku Ryoho, 2020, 47(6), 933-939.
[PMID: 32541171]
[107]
Taki, Y. Brain Aging Using Large Brain MRI Database.Aging Mechanisms: Longevity, Metabolism, and Brain Aging; Mori, N.; Mook-Jung, I., Eds.; Springer Japan: Tokyo, 2015, pp. 291-302.
[http://dx.doi.org/10.1007/978-4-431-55763-0_17]
[108]
Villa, J.K.D.; Diaz, M.A.N.; Pizziolo, V.R.; Martino, H.S.D. Effect of vitamin K in bone metabolism and vascular calcification: A review of mechanisms of action and evidences. Crit. Rev. Food Sci. Nutr., 2017, 57(18), 3959-3970.
[http://dx.doi.org/10.1080/10408398.2016.1211616] [PMID: 27437760]
[109]
Allison, A.C. The possible role of vitamin K deficiency in the pathogenesis of Alzheimer’s disease and in augmenting brain damage associated with cardiovascular disease. Med. Hypotheses, 2001, 57(2), 151-155.
[http://dx.doi.org/10.1054/mehy.2001.1307] [PMID: 11461163]
[110]
Tsukamoto, Y.; Ichise, H.; Kakuda, H.; Yamaguchi, M. Intake of fermented soybean (natto) increases circulating vitamin K2 (menaquinone-7) and γ-carboxylated osteocalcin concentration in normal individuals. J. Bone Miner. Metab., 2000, 18(4), 216-222.
[http://dx.doi.org/10.1007/s007740070023] [PMID: 10874601]
[111]
Buchanan, G.S.; Melvin, T.; Merritt, B.; Bishop, C.; Shuler, F.D. Vitamin K2 (Menaquinone) supplementation and its benefits in cardiovascular disease, osteoporosis, and cancer. Marshall J. Med., 2016, 2(3), 53.
[http://dx.doi.org/10.18590/mjm.2016.vol2.iss3.8]
[112]
Keyzer, C.A.; Vermeer, C.; Joosten, M.M.; Knapen, M.H.J.; Drummen, N.E.A.; Navis, G.; Bakker, S.J.L.; de Borst, M.H.; Vitamin, K. Vitamin K status and mortality after kidney transplantation: a cohort study. Am. J. Kidney Dis., 2015, 65(3), 474-483.
[http://dx.doi.org/10.1053/j.ajkd.2014.09.014] [PMID: 25453995]
[113]
Mansour, A.G.; Hariri, E.; Daaboul, Y.; Korjian, S.; El Alam, A.; Protogerou, A.D.; Kilany, H.; Karam, A.; Stephan, A.; Bahous, S.A. Vitamin K2 supplementation and arterial stiffness among renal transplant recipients-a single-arm, single-center clinical trial. J. Am. Soc. Hypertens., 2017, 11(9), 589-597.
[http://dx.doi.org/10.1016/j.jash.2017.07.001] [PMID: 28756183]
[114]
Shi, S.; Zheng, G.; Yang, C.; Chen, X.; Yan, Q.; Jiang, F.; Jiang, X.; Xin, Y.; Jiang, G. Effects of vitamin K3 combined with UVB on the proliferation and apoptosis of cutaneous squamous cell carcinoma A431 cells. OncoTargets Ther., 2019, 12, 11715-11727.
[http://dx.doi.org/10.2147/OTT.S228792] [PMID: 32099380]
[115]
Taper, H.S.; Keyeux, A.; Roberfroid, M. Potentiation of radiotherapy by nontoxic pretreatment with combined vitamins C and K3 in mice bearing solid transplantable tumor. Anticancer Res., 1996, 16(1), 499-503.
[PMID: 8615662]
[116]
Legault, J.; Tremblay, A.; Ramotar, D.; Mirault, M.E. Clusters of S1 nuclease-hypersensitive sites induced in vivo by DNA damage. Mol. Cell. Biol., 1997, 17(9), 5437-5452.
[http://dx.doi.org/10.1128/MCB.17.9.5437] [PMID: 9271420]
[117]
Ishibashi, M.; Arai, M.; Tanaka, S.; Onda, K.; Hirano, T. Antiproliferative and apoptosis-inducing effects of lipophilic vitamins on human melanoma A375 cells in vitro. Biol. Pharm. Bull., 2012, 35(1), 10-17.
[http://dx.doi.org/10.1248/bpb.35.10] [PMID: 22223331]
[118]
Fujita, H.; Tomiyama, J.; Tanaka, T. Vitamin K2 combined with all-trans retinoic acid induced complete remission of relapsing acute promyelocytic leukaemia. Br. J. Haematol., 1998, 584.
[119]
Yaguchi, M.; Miyazawa, K.; Katagiri, T.; Nishimaki, J.; Kizaki, M.; Tohyama, K.; Toyama, K. Vitamin K2 and its derivatives induce apoptosis in leukemia cells and enhance the effect of all-trans retinoic acid. Leukemia, 1997, 11(6), 779-787.
[http://dx.doi.org/10.1038/sj.leu.2400667] [PMID: 9177427]
[120]
Sakai, I.; Hashimoto, S.; Yoda, M.; Hida, T.; Ohsawa, S.; Nakajo, S.; Nakaya, K. Novel role of vitamin K2: a potent inducer of differentiation of various human myeloid leukemia cell lines. Biochem. Biophys. Res. Commun., 1994, 205(2), 1305-1310.
[http://dx.doi.org/10.1006/bbrc.1994.2807] [PMID: 7802663]
[121]
Tremante, E.; Santarelli, L.; Lo Monaco, E.; Sampaoli, C.; Ingegnere, T.; Guerrieri, R.; Tomasetti, M.; Giacomini, P. Sub-apoptotic dosages of pro-oxidant vitamin cocktails sensitize human melanoma cells to NK cell lysis. Oncotarget, 2015, 6(31), 31039-31049.
[http://dx.doi.org/10.18632/oncotarget.5024] [PMID: 26427039]
[122]
Tomasetti, M.; Nocchi, L.; Neuzil, J.; Goodwin, J.; Nguyen, M.; Dong, L.; Manzella, N.; Staffolani, S.; Milanese, C.; Garrone, B.; Alleva, R.; Borghi, B.; Santarelli, L.; Guerrieri, R. Alpha-tocopheryl succinate inhibits autophagic survival of prostate cancer cells induced by vitamin K3 and ascorbate to trigger cell death. PLoS One, 2012, 7(12)e52263
[http://dx.doi.org/10.1371/journal.pone.0052263] [PMID: 23272231]

Rights & Permissions Print Cite
Article Metrics
24
2
1
© 2024 Bentham Science Publishers | Privacy Policy